Meeting
2014 ASCO Annual Meeting
A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma.
Authors
David F. McDermott
Beth Israel Deaconess Medical Center, Boston, MA
David F. McDermott , Jeffrey R. Infante , Martin Henner Voss , Robert J. Motzer , John B. A. G. Haanen , Simon Chowdhury , Rodolfo F. Perini , Robert Iannone , Rachel Hodge , David Figueroa , Benjamin B. Suttle , Alicia Allred , Stephen D. Rubin , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02014636
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4604^)
DOI
10.1200/jco.2014.32.15_suppl.tps4604
Abstract #
TPS4604^
Poster Bd #
164B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
First Author: Georgina V. Long
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2022 ASCO Annual Meeting
KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
First Author: Philippe Armand